{"id":"capecitabine-endocrine-therapy","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Hand-foot skin reaction"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Stomatitis"},{"rate":"10-20","effect":"Myelosuppression"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and incorporates into DNA/RNA to impair cancer cell proliferation. Endocrine therapy (likely tamoxifen, aromatase inhibitor, or fulvestrant) blocks estrogen receptor function, preventing hormone-driven growth in estrogen receptor-positive breast cancer. The combination targets both proliferation and hormone dependence.","oneSentence":"Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, combined with endocrine therapy to block estrogen receptor signaling in hormone-responsive cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:49.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive metastatic or advanced breast cancer (in combination with endocrine therapy)"}]},"trialDetails":[{"nctId":"NCT07467330","phase":"PHASE3","title":"Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-11-15","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":40},{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":"Metastatic Breast Cancer","enrollment":541},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":"Advanced or Metastatic Breast Cancer","enrollment":866},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":"Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer","enrollment":297},{"nctId":"NCT07353437","phase":"PHASE2","title":"Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-31","conditions":"Breast Cancer","enrollment":334},{"nctId":"NCT05693766","phase":"PHASE2","title":"Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort","status":"RECRUITING","sponsor":"Sonya Reid","startDate":"2023-09-28","conditions":"Invasive Mammary Carcinoma, Metastatic Breast Cancer","enrollment":64},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT07071337","phase":"PHASE3","title":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2025-07-18","conditions":"Metastatic Breast Cancer","enrollment":430},{"nctId":"NCT06247995","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-08-14","conditions":"Breast Cancer","enrollment":58},{"nctId":"NCT05840211","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-08","conditions":"Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":654},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT06027541","phase":"","title":"Young Patients With Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08-01","conditions":"Breast Cancer Female","enrollment":1000},{"nctId":"NCT07005557","phase":"PHASE3","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1244},{"nctId":"NCT06643585","phase":"PHASE3","title":"A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2025-04-22","conditions":"Breast Cancer","enrollment":180},{"nctId":"NCT03227328","phase":"PHASE2","title":"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-08-02","conditions":"Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer","enrollment":52},{"nctId":"NCT05063136","phase":"PHASE3","title":"Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-09-28","conditions":"Breast Cancer","enrollment":1979},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT03355157","phase":"PHASE4","title":"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2018-03-01","conditions":"Metastatic Breast Cancer","enrollment":130},{"nctId":"NCT02028507","phase":"PHASE3","title":"Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2014-03-13","conditions":"Metastatic Breast Cancer","enrollment":693},{"nctId":"NCT06176534","phase":"PHASE2","title":"Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-01-01","conditions":"Advanced Breast Cancer, Treatment, HR Low/HER2 Negative","enrollment":240},{"nctId":"NCT06481553","phase":"","title":"RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-02-01","conditions":"Breast Cancer Stage IV","enrollment":480},{"nctId":"NCT02344472","phase":"PHASE3","title":"Detect V / CHEVENDO (Chemo vs. Endo)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2015-09","conditions":"Metastatic Breast Cancer","enrollment":271},{"nctId":"NCT01619111","phase":"PHASE3","title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2012-02","conditions":"HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells","enrollment":105},{"nctId":"NCT06375707","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-09","conditions":"Advanced Breast Cancer","enrollment":144},{"nctId":"NCT06339281","phase":"PHASE2","title":"A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Li Huiping","startDate":"2024-05-01","conditions":"Advanced Breast Cancer","enrollment":68},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT04383275","phase":"PHASE2","title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-08-23","conditions":"Breast Cancer","enrollment":356},{"nctId":"NCT05861271","phase":"PHASE2","title":"Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer Stage I","enrollment":1008},{"nctId":"NCT05861830","phase":"PHASE3","title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-15","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT03322215","phase":"PHASE2","title":"HR+/HER2- Advanced Breast Cancer and Endocrine Resistance","status":"TERMINATED","sponsor":"Theodoros Foukakis","startDate":"2017-10-24","conditions":"Breast Cancer Metastatic","enrollment":42},{"nctId":"NCT00665457","phase":"PHASE2","title":"Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-04-15","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT05212454","phase":"PHASE3","title":"Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-15","conditions":"Breast Cancer, Chemotherapy Effect","enrollment":400},{"nctId":"NCT03462251","phase":"PHASE3","title":"Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2018-05-24","conditions":"Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer","enrollment":41},{"nctId":"NCT05680194","phase":"","title":"Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-04-01","conditions":"Breast Cancer Female","enrollment":1000},{"nctId":"NCT00433589","phase":"PHASE3","title":"Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-02","conditions":"Breast Cancer","enrollment":6600},{"nctId":"NCT05411380","phase":"PHASE2","title":"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.","status":"UNKNOWN","sponsor":"wang shusen","startDate":"2022-10-03","conditions":"Breast Cancer","enrollment":73},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer, Metastatic Cancer","enrollment":319},{"nctId":"NCT05345860","phase":"NA","title":"Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-03-24","conditions":"Early-stage Breast Cancer","enrollment":300},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT04922008","phase":"PHASE2","title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":356},{"nctId":"NCT04571437","phase":"PHASE2","title":"Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-03-01","conditions":"Breast Cancer, Estrogen Receptor-positive Breast Cancer, Metastatic Breast Cancer","enrollment":204},{"nctId":"NCT04498793","phase":"PHASE2","title":"Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-09","conditions":"HER2-negative Breast Cancer","enrollment":55},{"nctId":"NCT01950182","phase":"PHASE3","title":"Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2013-09-16","conditions":"Breast Cancer","enrollment":392},{"nctId":"NCT04258163","phase":"","title":"Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2019-01-01","conditions":"Metastatic Breast Cancer","enrollment":760},{"nctId":"NCT04095390","phase":"PHASE2","title":"A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2019-09-30","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT04012918","phase":"PHASE2","title":"Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2018-08-30","conditions":"Metastatic Breast Cancer","enrollment":124},{"nctId":"NCT00006023","phase":"PHASE2","title":"Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2000-03","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT03541863","phase":"","title":"Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Fudan University","startDate":"2017-10-10","conditions":"Breast Cancer","enrollment":131},{"nctId":"NCT00684216","phase":"PHASE2, PHASE3","title":"Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer","status":"TERMINATED","sponsor":"The Netherlands Cancer Institute","startDate":"2008-04","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT00194792","phase":"PHASE2","title":"Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2005-08","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer","enrollment":28},{"nctId":"NCT03204734","phase":"PHASE2","title":"Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-01-01","conditions":"Breast Cancer","enrollment":132},{"nctId":"NCT02597868","phase":"NA","title":"A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2013-01","conditions":"Breast Cancer","enrollment":132},{"nctId":"NCT01641406","phase":"PHASE2","title":"\"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer\"","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2011-03","conditions":"Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2701189,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Experimental group"],"phase":"phase_3","status":"active","brandName":"Capecitabine+endocrine therapy","genericName":"Capecitabine+endocrine therapy","companyName":"Henan Cancer Hospital","companyId":"henan-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, combined with endocrine therapy to block estrogen receptor signaling in hormone-responsive cancers. Used for Hormone receptor-positive metastatic or advanced breast cancer (in combination with endocrine therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}